TY - JOUR T1 - From predictions to prescriptions: A data-driven response to COVID-19 JF - medRxiv DO - 10.1101/2020.06.26.20141127 SP - 2020.06.26.20141127 AU - Dimitris Bertsimas AU - Leonard Boussioux AU - Ryan Cory-Wright AU - Arthur Delarue AU - Vasileios Digalakis AU - Alexandre Jacquillat AU - Driss Lahlou Kitane AU - Galit Lukin AU - Michael Li AU - Luca Mingardi AU - Omid Nohadani AU - Agni Orfanoudaki AU - Theodore Papalexopoulos AU - Ivan Paskov AU - Jean Pauphilet AU - Omar Skali Lami AU - Bartolomeo Stellato AU - Hamza Tazi Bouardi AU - Kimberly Villalobos Carballo AU - Holly Wiberg AU - Cynthia Zeng Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/29/2020.06.26.20141127.abstract N2 - The COVID-19 pandemic has created unprecedented challenges worldwide. Strained healthcare providers make difficult decisions on patient triage, treatment and care management on a daily basis. Policy makers have imposed social distancing measures to slow the disease, at a steep economic price. We design analytical tools to support these decisions and combat the pandemic. Specifically, we propose a comprehensive data-driven approach to understand the clinical characteristics of COVID-19, predict its mortality, forecast its evolution, and ultimately alleviate its impact. By leveraging cohort-level clinical data, patient-level hospital data, and census-level epidemiological data, we develop an integrated four-step approach, combining descriptive, predictive and prescriptive analytics. First, we aggregate hundreds of clinical studies into the most comprehensive database on COVID-19 to paint a new macroscopic picture of the disease. Second, we build personalized calculators to predict the risk of infection and mortality as a function of demographics, symptoms, comorbidities, and lab values. Third, we develop a novel epidemiological model to project the pandemic’s spread and inform social distancing policies. Fourth, we propose an optimization model to reallocate ventilators and alleviate shortages. Our results have been used at the clinical level by several hospitals to triage patients, guide care management, plan ICU capacity, and re-distribute ventilators. At the policy level, they are currently supporting safe back-to-work policies at a major institution and equitable vaccine distribution planning at a major pharmaceutical company, and have been integrated into the US Center for Disease Control’s pandemic forecast.Significance Statement In the midst of the COVID-19 pandemic, healthcare providers and policy makers are wrestling with unprecedented challenges. How to treat COVID-19 patients with equipment shortages? How to allocate resources to combat the disease? How to plan for the next stages of the pandemic? We present a data-driven approach to tackle these challenges. We gather comprehensive data from various sources, including clinical studies, electronic medical records, and census reports. We develop algorithms to understand the disease, predict its mortality, forecast its spread, inform social distancing policies, and re-distribute critical equipment. These algorithms provide decision support tools that have been deployed on our publicly available website, and are actively used by hospitals, companies, and policy makers around the globe.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo Funding SourceAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Massachusetts Institute of Technology Committee on the Use of Humans as Experimental Subjects provided approval for the clinical research in this paper. The Protocol number is 2004000140A001.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGeneral overview of the data and results are available at our website https://www.covidanalytics.io/. Clinical data is withheld under IRB rules. https://github.com/COVIDAnalytics/website ER -